A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.
Alexandra Twin has 15+ years of experience as an editor and writer, covering financial news for public and private companies. Ebony Howard is a certified public accountant and a QuickBooks ProAdvisor ...
Daniel Liberto is a journalist with over 10 years of experience working with publications such as the Financial Times, The Independent, and Investors Chronicle. Investopedia / Jake Shi A restatement ...
Excellergy, a biotech developing a new class of allergy therapeutics, has announced its launch with a $70 million Series A financing to advance its pipeline of first-in-class effector cell response ...
The "Biotechnology Market - Therapeutic Innovations & Forecast 2025-2033" report has been added to ResearchAndMarkets.com's offering.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback